Chrysalis

Chrysalis is a SAMHSA-registered addiction-treatment facility located at Eureka, MT. The facility offers specific levels of care: Inpatient, Dual Dx. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at Chrysalis

Level-of-care documentation: The facility's documented care levels are The facility offers specific levels of care: Inpatient, Dual Dx. — each of which is appropriate for specific clinical presentations. Matching the level to the specific clinical need is the pre-admission work. Under MHPAEA 2024 medical-necessity criteria disclosure, plan-specific criteria for each of these levels must be available to patients upon request. Mismatch between documented clinical need and offered level of care is a common source of authorization denial.

Insurance and payment

Chrysalis operates primarily on commercial insurance. The implication for patients: higher typical cost-share, potentially more intensive programming, and the full burden of MHPAEA parity-rule dynamics — including appeal rights when the plan denies. Benefit verification should be obtained in writing prior to admission and should document: network contract status for the specific insurance product, prior authorization requirements and approved day-count, applicable cost-sharing structure, and out-of-network secondary coverage (where applicable). Proceeding on verbal VOB creates material risk of post-admission benefit dispute.

Specialty programming

The facility's documented specialty programming includes: Members of military families, Clients with co-occurring mental and substance use disorders, Clients who have experienced trauma. Clinical verification of specialty programming should encompass credentialed staff profile, programming-hour documentation, and specialty-specific medical-necessity documentation for third-party authorization. The MHPAEA 2024 rule addresses specialty-program network adequacy for patients requiring specific clinical capabilities.

Before you call

Pre-admission due-diligence for Chrysalis: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via MT behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether Chrysalis offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.